OOIR: Observatory of International Research

Papers

(The H4-Index of Allergy is 55. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
Impact of atopic respiratory disease on contact dermatitis	650
Issue Information	323
Clinical applicability of the urticaria control test in patients with chronic urticaria: Further evidence from 622 adult and pediatric patients with different disease subtypes	265
Bacillus Calmette–Guérin vaccination to prevent childhood asthma: A revised meta‐analysis	231
Reply to correspondence: Basophil reactivity to BNT162b2 in COVID‐19 convalescence	183
Reply to: “Phase 2a randomized clinical trial of dupilumab (anti‐IL‐4Rα) for alopecia areata patients”	162
Notch4, uncovering an immunomodulator in allergic asthma	152
Group 2 innate lymphoid cells in patients with nonasthmatic eosinophilic bronchitis	143
Large scale regulatory T cells screening	137
Comparison of social network engagement performance between artificial intelligence‐generated content and human experts: A study in the field of immunology and allergology	135
Type 2 memory B cells: The repository of allergic memory?	128
Algorithms in allergy: An algorithm for alpha‐Gal syndrome diagnosis and treatment, 2024 update	112
Mepolizumab depletes inflammatory but preserves homeostatic eosinophils in severe asthma	111
More than half of chronic rhinosinusitis with nasal polyps (CRSwNP) patients treated with dupilumab experience early and fast olfactory improvement within 28 days	108
Correspondence: Proposed amendment to the nomenclature of allergic diseases and hypersensitivity reactions: Looking beyond the classic paradigms	105
	105
Extracellular vesicle microRNA signatures as novel biomarkers in obese asthmatics	99
Correspondence to “Allergic bronchopulmonary aspergillosis with atopic, nonatopic, and sans asthma—Factor analysis”	94
Correspondence to ‘association between chronic rhinosinusitis and new onset asthma implications for prevention’	93
Autologous Th2‐polarized lymphocytes induce atopic dermatitis lesions in non‐atopic human skin xenotransplants	91
In vitro data suggest that Indian delta variant B.1.617 of SARS‐CoV‐2 escapes neutralization by both receptor affinity and immune evasion	89
Issue Information	88
A Silver (Birch) Bullet for Children With Tree Pollen Allergy: Single Allergen Immunotherapy With Birch Extract Protects Across the Birch Homologous Group Pollen Season	87
Cross‐protection of allergen immunotherapy‐induced antibodies to related allergens requires a high degree of structural identity	86
One‐strength dose escalation of house dust mite depot product for subcutaneous immunotherapy is safe and tolerable	85

Allergen immunotherapy adverse events in adults with respiratory allergies‐data from ADER: An EAACI task force report	79
Differentiation of COVID‐19 signs and symptoms from allergic rhinitis and common cold: An ARIA‐EAACI‐GA²LEN consensus	78
The impact of outdoor pollution and extreme temperatures on asthma‐related outcomes: A systematic review for the EAACI guidelines on environmental science for allergic diseases and asthma	78
Adding the variable of environmental complexity into the COVID‐19 pandemic equation	75
Ovomucoid‐specific IgD increases in children who naturally outgrow egg allergy in a cross‐sectional study	75
Safe administration of the Pfizer‐BioNtTech COVID‐19 vaccine following an immediate reaction to the first dose	75
Pre‐existing inflammation reduces the response to contact allergens in Tmem79‐deficient mice	71
Ambient pollen exposure and pollen allergy symptom severity in the EPOCHAL study	70
Climate crisis paralysis: Accelerating global action for health resilience in a changing world	69
IL1RAP expression and the enrichment of IL‐33 activation signatures in severe neutrophilic asthma	68
IDO1 and FOXP3: Possible immune‐regulating genes alleviating cedar pollinosis via L. plantarum YIT 0132	68
Reply to correspondence: “Is Helicobacter pylori infection inversely correlated with atopic, skin, and autoimmune diseases?”	68
Legends of allergy and immunology: Kurt Blaser and major contributions to deciphering the role of T cells in allergic disease	67
Some OPA once told me “LKB1 is going to rule me”: The OPA1‐LKB1 axis in immune response	64
In this issue: Graphical Abstract	63
Introducing peanut early in life – Ready for the general population?	63
Issue Information	63
Long‐term aspirin desensitization has mucosal cytokine features of immune tolerance	61
Blockade of sphingosine‐1‐phosphate receptor 4 pathway has anti‐inflammatory effects in a murine model of allergic airway inflammation	61
Comparative assessment of allergic reactions to COVID‐19 vaccines in Europe and the United States	59
The contribution of digital health to net zero patient care in allergic diseases: From concept to practice	59
Maternal and infant serum carotenoids are associated with infantile atopic dermatitis development	58
Prospective studies are needed to elucidate the clinical impact of predominant Api m 10 sensitization	57
In memoriam: Lawrence M. Lichtenstein (1934–2022)	56
HLA‐DPB105:01* genotype is associated with poor response to sublingual immunotherapy for Japanese cedar pollinosis	56
Epigenome‐Wide Association Study of Asthma Exacerbations in Europeans	56
Association Between Long‐Term Exposure to Ambient Air Pollution and the Risk of Recurrent Asthma Hospitalizations	55
In Memory of Dr. Izabela Kuprys‐Lipinska: A Pioneering Clinician, Scientist, and Beloved Friend	55
Assessing IgE and basophil activity in blood samples from nonhuman primates	55
Oral and Gut Microbial Hubs Associated With Reaction Threshold Interact With Circulating Immune Factors in Peanut Allergy	55
Association of cytotoxic effector memory CD8⁺ T cells with sustained unresponsiveness after peanut oral immunotherapy	55